

Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B) has, by information previously announced, conducted a directed share issue. Through the first registration of the new issue, the number of shares has increased by 53,333,333 B-shares and the number of votes has increased by 53,333,333. The total number of shares amounts to 144,264,088, of which 971,024 are A shares and 143,293,064 are B shares. The total number of votes after the conversions amounts to 146,206,136. The share capital has increased by SEK 16,013,542.99 and now amounts to SEK 43,315,859.79.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

Veronica Wallin, CFO, Episurf Medical

Tel: +46 (0) 700 37 48 95

Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CEST on March 31, 2020.